Andres Maldonado
Stock Analyst at HC Wainwright & Co.
(2.20)
# 2,734
Out of 4,944 analysts
86
Total ratings
35.29%
Success rate
-0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMAB I-Mab | Reiterates: Buy | $7 | $3.85 | +81.82% | 1 | Jul 9, 2025 | |
| IBRX ImmunityBio | Reiterates: Buy | $8 | $2.47 | +223.89% | 4 | Jun 4, 2025 | |
| AURA Aura Biosciences | Assumes: Buy | $22 | $6.94 | +217.00% | 1 | May 28, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $10 | $1.41 | +609.22% | 1 | May 15, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $50 → $40 | $8.96 | +346.43% | 2 | May 7, 2025 | |
| TCRX TScan Therapeutics | Maintains: Buy | $15 → $10 | $1.67 | +498.80% | 1 | May 7, 2025 | |
| ERAS Erasca | Reiterates: Buy | $6 | $1.56 | +284.62% | 10 | Apr 30, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $13 | $4.87 | +166.94% | 1 | Apr 30, 2025 | |
| STRO Sutro Biopharma | Reiterates: Neutral | $2 | $0.78 | +155.20% | 1 | Apr 29, 2025 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $3.07 | +649.19% | 1 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $24.98 | +200.24% | 13 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $6.14 | +486.32% | 14 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.66 | +261.45% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.19 | +1,160.50% | 16 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.64 | +586.81% | 2 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $50 | $32.20 | +55.28% | 13 | Nov 26, 2024 |
I-Mab
Jul 9, 2025
Reiterates: Buy
Price Target: $7
Current: $3.85
Upside: +81.82%
ImmunityBio
Jun 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.47
Upside: +223.89%
Aura Biosciences
May 28, 2025
Assumes: Buy
Price Target: $22
Current: $6.94
Upside: +217.00%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Buy
Price Target: $10
Current: $1.41
Upside: +609.22%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $8.96
Upside: +346.43%
TScan Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $1.67
Upside: +498.80%
Erasca
Apr 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.56
Upside: +284.62%
Foghorn Therapeutics
Apr 30, 2025
Reiterates: Buy
Price Target: $13
Current: $4.87
Upside: +166.94%
Sutro Biopharma
Apr 29, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.78
Upside: +155.20%
Protara Therapeutics
Apr 28, 2025
Reiterates: Buy
Price Target: $23
Current: $3.07
Upside: +649.19%
Apr 28, 2025
Reiterates: Buy
Price Target: $75
Current: $24.98
Upside: +200.24%
Apr 3, 2025
Reiterates: Buy
Price Target: $36
Current: $6.14
Upside: +486.32%
Mar 26, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.66
Upside: +261.45%
Mar 12, 2025
Reiterates: Buy
Price Target: $15
Current: $1.19
Upside: +1,160.50%
Mar 11, 2025
Reiterates: Buy
Price Target: $25
Current: $3.64
Upside: +586.81%
Nov 26, 2024
Maintains: Buy
Price Target: $40 → $50
Current: $32.20
Upside: +55.28%